- Raw materials
- Antibacterials
- Rokitamycin
Rokitamycin API Manufacturers & Suppliers
0 verified results
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Rokitamycin | CAS No: 74014-51-0 | GMP-certified suppliers
A medication that serves as a systemic antibacterial agent targeting bacterial infections with potential CYP3A enzyme inhibition for research and development in anti-infective therapies.
Therapeutic categories
Product Snapshot
- Rokitamycin is an oral small molecule antibiotic available in various solid dosage forms including granules for suspension, tablets (coated and film-coated), and powder
- It is primarily indicated for antibacterial use targeting susceptible bacterial infections
- Rokitamycin is currently in the experimental stage and has not received regulatory approval from major agencies such as FDA or EMA
Clinical Overview
While specific clinical indications for Rokitamycin have not been clearly established, macrolides generally target bacterial infections by interfering with bacterial protein synthesis. These agents typically bind to the 50S ribosomal subunit, inhibiting translocation and peptide elongation, thus exerting a bacteriostatic effect. Rokitamycin's exact mechanism of action has yet to be fully characterized but is expected to align with this pharmacological profile.
Pharmacokinetic data for Rokitamycin remain limited due to its experimental status. However, as a CYP3A and CYP3A4 inhibitor, it has potential implications for drug-drug interactions affecting the metabolism of co-administered substrates of these enzymes. Absorption, distribution, metabolism, and excretion (ADME) parameters have not been comprehensively reported.
Safety and toxicity profiles have not been definitively delineated. Nonetheless, general considerations for macrolides include potential hepatotoxicity, QT interval prolongation, and hypersensitivity reactions. Rigorous preclinical and clinical toxicology assessments will be required before clinical application.
No approved pharmaceutical brands or marketed products currently exist for Rokitamycin. Its usage context remains confined to research settings.
For API procurement, potential suppliers should ensure compliance with relevant pharmacopeial standards and Good Manufacturing Practice (GMP) guidelines. Purity, characterization, and impurity profiles must be thoroughly documented to support regulatory submissions and formulation development. Given its cytochrome P450 inhibitory properties, careful evaluation of batch consistency is advisable to mitigate variability in clinical or experimental outcomes.
Identification & chemistry
| Generic name | Rokitamycin |
|---|---|
| Molecule type | Small molecule |
| CAS | 74014-51-0 |
| UNII | ZPT03UEM0E |
| DrugBank ID | DB13409 |
Formulation & handling
- Rokitamycin is formulated for oral administration, primarily as tablets and granules for suspension.
- As an aminoglycoside antibiotic, it is a small molecule with moderate lipophilicity and low water solubility, which may influence formulation design.
- Stability and handling should consider its peptide-like amino sugar structure but no specific injectable formulation or special food sensitivity is indicated.
Regulatory status
Rokitamycin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
